Tumor size and prognosis in aggressively treated osteosarcoma.
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
PURPOSE: The aim of this retrospective analysis was to investigate the prognostic significance and optimal measures of tumor size in osteosarcoma treated with intensive neoadjuvant chemotherapy. PATIENTS AND METHODS: Initial anterior-posterior (AP) and lateral x-ray films of 128 patients treated within the trials Cooperative Osteosarcoma Study (COSS)-80, -82, and -86, were evaluated for the following three tumor diameters: length, width, and depth. Metastasis-free survival (MFS) analyses were performed in univariate and multivariate models with one, two, and three dimensions of the tumor as absolute or relative measures (tumor length, referred to bone length, plane and volume to body-surface area). RESULTS: Univariate analyses of MFS showed a high prognostic significance of all absolute measures. Relative measures, at best, showed a comparable predictive value. Cox regression analysis indicated the high prognostic significance of absolute tumor volume (ATV; P < .0001) and histologic response (P < .0001). None of 19 patients with an ATV < or = 70 cm3 and only four of 53 with an ATV < or = 150 cm3 relapsed, while in patients with an ATV more than 150 cm3, the relapse rate remained 40% to 60%, irrespective of further increase in volume. CONCLUSION: Initial tumor size is an important and easily obtainable prognostic factor in osteosarcoma and may serve as a basis for risk-adapted therapy. It is best represented by the absolute three-dimensional measure ATV. There is a cut-off point regarding the incidence of metastases at a tumor volume of approximately 150 cm3 as calculated from two-plane x-ray films.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,204
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
Eilber, F., Giuliano, A., Eckardt, J., Patterson, K., Moseley, S., & Goodnight, J. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.21 · Cited by 529
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
Self-citationPrognostic factors in osteosarcoma: a critical review.
Davis, A. M., Bell, R. S., & Goodwin, P. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.423 · Cited by 424
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., Brandeis, W., Ebell, W., Erttmann, R., & Göbel, U. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.617 · Cited by 345
Self-citationBramwell, V. H., Burgers, M., Sneath, R., Souhami, R., van Oosterom, A. T., Voûte, P. A., Rouesse, J., Spooner, D., Craft, A. W., & Somers, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1579 · Cited by 313
Glasser, D. B., Lane, J. M., Huvos, A. G., Marcove, R. C., & Rosen, G. (1992) · Cancer · doi:10.1002/1097-0142(19920201)69:3<698::aid-cncr2820690317>3.0.co;2-g · Cited by 282
Bacci, G., Picci, P., Ruggieri, P., Mercuri, M., Avella, M., Capanna, R., Brach Del Prever, A., Mancini, A., Gherlinzoni, F., Padovani, G., et al. (1990) · Cancer · doi:10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m · Cited by 235
Cited by
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Self-citationLindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Fuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Self-citationOsteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
Ozaki, T., Flege, S., Kevric, M., Lindner, N., Maas, R., Delling, G., Schwarz, R., von Hochstetter, A. R., Salzer-Kuntschik, M., Berdel, W. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.142 · Cited by 342
Self-citationOsteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Duchman, K. R., Gao, Y., & Miller, B. J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.05.001 · Cited by 305
Expression of HER2/erb B-2 Correlates With Survival in Osteosarcoma
Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 303
Current Treatment of Osteosarcoma
Ferguson, W. S., & Goorin, A. M. (2001) · Cancer Investigation · doi:10.1081/cnv-100102557 · Cited by 295
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00105-5 · Cited by 262
A review of clinical and molecular prognostic factors in osteosarcoma
Clark, J. C. M., Dass, C. R., & Choong, P. F. M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0330-x · Cited by 250
“…absolute tumour volume, stage and site of the tumour remain the most useful because in general they have clear cut-oV points identiWed in the literature between good and bad outcomes, for example age greater than 40 (Aksnes et al. 2006), and tumour volume greater than 150 cm3 (Bieling et al. 1996).”
BackgroundInfluentialPrognostic factors in localized extremity osteosarcoma: A systematic review
Bramer, J. A. M., van Linge, J. H., Grimer, R. J., & Scholten, R. J. P. M. (2009) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2009.01.011 · Cited by 177
Lascelles, B. D. X., Dernell, W. S., Correa, M. T., Lafferty, M., Devitt, C. M., Kuntz, C. A., Straw, R. C., & Withrow, S. J. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.01.011 · Cited by 164
Ferrari, S., Bacci, G., Picci, P., Mercuri, M., Briccoli, A., Pinto, D., Gasbarrini, A., Tienghi, A., & Brach del Prever, A. (1997) · Annals of Oncology · doi:10.1023/a:1008221713505 · Cited by 116
“Other factors such as sex, tumor site and tumor size, which were considered significant predictive factors for survival by several authors [25—27] showed no significant importance in our study.”
BackgroundCurrent Concepts in the Evaluation and Treatment of Osteosarcoma
Papagelopoulos, P. J., Galanis, E. C., Vlastou, C., Nikiforidis, P. A., Vlamis, J. A., Boscainos, P. J., Fragiadakis, E. G., Stamos, K. G., Pantazopoulos, T., & Sim, F. H. (2000) · Orthopedics · doi:10.3928/0147-7447-20000801-11 · Cited by 42
Metadata
- Authors
- Bieling, P., Rehan, N., Winkler, P., Helmke, K., Maas, R., Fuchs, N., Bielack, S., Heise, U., Jurgens, H., Treuner, J., Romanowski, R., Exner, U., Kotz, R., & Winkler, K.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-03
- Volume
- 14
- Issue
- 3
- Pages
- 848-858
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1857092002
- Cited by
- 275
- References
- 24
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.